Navigation Links
Xlumena Closes Series C Financing; Focuses on Expanding Global Commercial Presence and Obtaining FDA Clearance
Date:12/3/2013

MOUNTAIN VIEW, Calif., Dec. 3, 2013 /PRNewswire/ -- Xlumena, Inc., a leader in the development of advanced endoscopic devices, today announced the close of a $25 million Series C financing.  Led by Third Point LLC, the round of funding includes existing investors Prism VentureWorks, Charter Life Sciences, Ascent Biomedical Ventures and Aperture Venture Partners.  Xlumena will use the Series C proceeds to expand global commercialization efforts for its AXIOS family of devices and continue the process of bringing this innovative platform to the US interventional endoscopy community. 

Xlumena's principal product, the AXIOS Stent and Delivery System, obtained a CE mark designation in Europe in 2012 and is available in a select number of centers.  The AXIOS Stent, a fully-covered, dual-flanged stent, is delivered under endoscopic ultrasound guidance and designed to create a secure drainage pathway between the gastrointestinal tract and the common bile duct, gallbladder or pseudocyst.  The HOT AXIOS, also available in Europe, incorporates cautery into the delivery system, enabling access and stent delivery in a single device.  The AXIOS devices have been used in the treatment of acute cholecystitis, biliary inflammation associated with strictures or stones in the bile duct, and pancreatic pseudocysts.

Greg Patterson, President and CEO of Xlumena, commented: "As a company, we have always focused on the needs of interventional endoscopists. This financing will allow us to better meet the global commercial demand and provide a springboard for an initial launch of the AXIOS in the United States once FDA clearance is granted. We look forward to this new collaboration with Third Point and a continued partnership with our existing investors."  Jason Hong Ph.D. will represent Third Point LLC on the Xlumena Board of Directors. 

For more information about the AXIOS Stent and Delivery System, please visit www.xlumena.com.

About Xlumena, Inc.: Xlumena is the leader in developing products that enable advanced image-guided endoscopy procedures. These innovations will allow endoscopists to offer minimally invasive alternatives to patients suffering from common gastrointestinal and biliary conditions. Pioneering interventional endoscopists around the world are using Xlumena's products to extend their therapeutic reach. 

About Third Point: Third Point LLC is an SEC-registered investment adviser headquartered in New York. Founded in 1995, Third Point follows an event-driven approach to global investing.

CAUTION: The AXIOS and HOT AXIOS devices have CE mark designation in Europe. They are not available for sale in the United States. 


'/>"/>
SOURCE Xlumena, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Tyber Medical Closes Private Placement Funding Round
2. Catabasis Closes $32.4 Million Series B Financing
3. CorMedix Inc. Closes $3,000,000 Preferred Stock Offerings
4. TREVENTIS Corporation Closes $4.4 Million Financing with Wellcome Trust
5. Apama Medical, A Shifamed Portfolio Company, Closes $3.2M Series A-1 Financing Round
6. MEDTEC China 2013: Conference Program Closes in on Finalization
7. Drip Drop Inc. closes $3.0M Series A-1 round with investments from John Elway, Ronnie Lott, and Sam Nazarian.
8. Acutus Medical Closes Series B Funding at $28 Million
9. Organovo Holdings, Inc. Closes $46.6 Million Public Offering of Common Stock and Exercise of Over-Allotment Option
10. Endexx closes Acquisition of Dispense Labs LLC.
11. AuraSense Therapeutics Closes Tranche II of Series B Equity Investment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
(Date:6/24/2016)... ... 2016 , ... Today, MTI-GlobalStem, a provider of optimized transfection ... to transfect cells, announces its launch of the PluriQ™ G9™ Gene Editing System ... is a complete system for culturing and transfecting human pluripotent stem cells for ...
Breaking Medicine News(10 mins):